Compare MASS & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | MDWD |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.0M | 224.6M |
| IPO Year | 2020 | 2014 |
| Metric | MASS | MDWD |
|---|---|---|
| Price | $6.35 | $18.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 378.4K | 133.2K |
| Earning Date | 03-03-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,045,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $12.77 |
| Revenue Next Year | $19.55 | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.21 | 6.15 |
| 52 Week Low | $1.92 | $14.14 |
| 52 Week High | $9.34 | $22.51 |
| Indicator | MASS | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 49.31 |
| Support Level | $6.06 | $17.01 |
| Resistance Level | $6.90 | $18.48 |
| Average True Range (ATR) | 0.41 | 0.76 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 41.67 | 66.13 |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.